Current Assets
Accounts Receivable
Regeneron Pharmaceuticals Accounts Receivable decreased by 0.2% to $5.73B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.1%, from $5.56B to $5.73B. Over 5 years (FY 2020 to FY 2025), Accounts Receivable shows an upward trend with a 6.9% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026Apr 29, 2026
How to read this metric
Rapid growth relative to sales may indicate collection issues or aggressive revenue recognition; stability suggests efficient cash conversion.
Detailed definition
This represents the total amount owed to the company by customers for goods or services delivered, minus the allowance f...
Peer comparison
Standard metric for all companies with B2B or credit-based sales models.
Metric ID:
accounts_receivable_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.00B | $5.45B | $6.04B | $4.84B | $5.16B | $5.55B | $5.33B | $5.12B | $5.12B | $5.58B | $5.67B | $5.22B | $5.72B | $6.11B | $6.21B | $5.56B | $5.61B | $5.69B | $5.74B | $5.73B |
| QoQ Change | — | -22.1% | +10.7% | -19.8% | +6.7% | +7.5% | -4.0% | -3.9% | +0.1% | +9.0% | +1.5% | -7.9% | +9.5% | +6.8% | +1.7% | -10.5% | +0.9% | +1.4% | +0.9% | -0.2% |
| YoY Change | — | — | — | — | -26.3% | +1.8% | -11.7% | +5.8% | -0.8% | +0.7% | +6.4% | +2.0% | +11.6% | +9.4% | +9.6% | +6.5% | -1.9% | -6.9% | -7.6% | +3.1% |
Range$4.84B – $7.00B
CAGR-4.1%
Avg YoY Growth+0.1%
Median YoY Growth+1.9%
Accounts Receivable at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's accounts receivable?
- Regeneron Pharmaceuticals (REGN) reported accounts receivable of $5.73B in Q1 2026.
- How has Regeneron Pharmaceuticals's accounts receivable changed year-over-year?
- Regeneron Pharmaceuticals's accounts receivable increased by 3.1% year-over-year, from $5.56B to $5.73B.
- What is the long-term trend for Regeneron Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's accounts receivable has grown at a 6.9% compound annual growth rate (CAGR), from $4.11B to $5.74B.
- What does accounts receivable mean?
- The net amount of money owed by customers after accounting for potential non-payments.